EGFR and type 2 diabetes mellitus: In summary, we concluded that peripheral blood-derived Exos from T2D patients carry miR-135a-3p into HVSMCs, which activates the ErbB signaling pathway by inhibiting ATM, thereby promoting vascular injury in T2D (Figure 9).